NCT05827081 2026-04-14
Adjuvant WIDER
Novartis
Phase 3 Recruiting
Novartis
Stemline Therapeutics, Inc.
University of Southern California
Dana-Farber Cancer Institute
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Regina Elena Cancer Institute